Search Results
Your search for The ASCO Post matches 17139 pages
Showing 5651 - 5700Phase II TRITON2 Study in Metastatic Castration-Resistant Prostate Cancer
The single-arm TRITON2 study demonstrated the efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer.1,2 Results from the study (ClinicalTrials.gov identifier NCT02952534) led to the approval of rucaparib in this...
Final Analysis of the ARAMIS Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer
A year ago, initial results from the double-blind, multicenter, randomized phase III ARAMIS clinical trial evaluating the efficacy and safety of darolutamide, a structurally unique androgen-receptor antagonist, in men with nonmetastatic castration-resistant prostate cancer, were published in The...
Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer
In the final overall survival analysis of the phase III PROSPER trial reported at the ASCO20 Virtual Scientific Program1 and published in The New England Journal of Medicine,2 Cora N. Sternberg, MD, and colleagues found that enzalutamide plus androgen-deprivation therapy (ADT) significantly...
Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial
As reported at the ASCO20 Virtual Scientific Program1 and in The New England Journal of Medicine2 by Neal D. Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, South Carolina, and colleagues, the phase III HERO trial showed sustained castrate testosterone levels and lower risk of...
In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial of any PSMA-targeted therapy and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...
Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer
Initial results of the randomized phase II TheraP trial showed that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177–labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic...
Genitourinary Oncology Highlights 2019–2020 Almanac
Over the past year, we have seen significant advances in the treatment of prostate, kidney, and urothelial cancers that will benefit patients now and in the future. We have learned about the final results of important clinical trials across multiple genitourinary cancers disease states leading to...
Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities
Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus...
Kala Visvanathan, MD, on Ovarian Cancer: Lowering Mortality With Lipophilic Statins
Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses her analysis of data from more than 10,000 women with ovarian cancer. The results suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduced ovarian cancer death rates (Abstract ...
ASH Releases New Clinical Practice Guidelines on the Treatment of Older Adults With Newly Diagnosed Acute Myeloid Leukemia
The American Society of Hematology (ASH) has published new guidelines to help older adults with acute myeloid leukemia (AML) and their health-care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice...
UICC Applauds WHO Global Strategy on Eliminating Cervical Cancer as a Public Health Problem
The Union for International Cancer Control (UICC) lauded the adoption of the World Health Organization’s (WHO) global strategy toward eliminating cervical cancer as a public health problem. WHO Member States adopted the strategy alongside other health resolutions as part of the silence procedure...
Update on Detecting and Treating Biologically Diverse Neuroendocrine Tumors
Neuroendocrine tumors are rare malignancies that arise in neuroendocrine cells, which can occur throughout the body but are most commonly found in the gastrointestinal tract, lungs, and pancreas. Although most neuroendocrine tumors are indolent and take years to grow, some are aggressive and grow...
10-Year Study Indicates Pembrolizumab Provides Long-Term Benefits for Patients With Metastatic Melanoma
A new 10-year analysis, led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and recently published in JAMA Oncology,1 provides new insights into an important question: whether BRAF V600E/K–mutation status or ...
Having Cancer Has Not Affected Me in Any Negative Way
I have witnessed much sickness and death over my 35-year career as a medical oncologist. During the early years of my career, I had difficulty dealing with the sickness and death I witnessed on a regular basis. As a result, with help from the Hindu scripture of Bhagavad Gita, I have trained my...
Stand Up To Cancer Announces New Research and Education Effort to Improve Care for Underserved Patients With Lung Cancer
Stand Up To Cancer (SU2C) recently announced a $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health-care equity for underserved patients with lung cancer, including Black individuals and those living in rural communities. The disease remains...
New Effort to Address Health Disparities for Black Men
The Prostate Cancer Foundation and Robert F. Smith, Founder, Chairman and Chief Executive Officer (CEO) of Vista Equity Partners, have announced a new effort to reduce deaths from prostate cancer, one of the largest health disparities facing Black men today. “As African American men are at an...
A Health-Care Journalist Explores Breast Cancer in America, Through the Lens of Her Own Diagnosis
Great strides in research and clinical practice have decreased breast cancer mortality rates by more than 35% since 1990, yet about 40,000 American women die of the disease each year. In Radical: The Science, Culture, and History of Breast Cancer in America, health-care journalist Kate Pickert...
Physicians, New Drugs, and Pharma
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved record numbers of new cancer drugs recently. This is extraordinarily good news for physicians, patients, and drug companies, but it raises important questions as to how effective these drugs are, whether...
Florida Cancer Specialists Appoints New Chief Executive Officer
Florida Cancer Specialists and Research Institute (FCS) announced its Chief Financial Officer, Nathan H. Walcker, MBA, has been named Chief Executive Officer (CEO). Mr. Walcker succeeds the current CEO, Brad Prechtl, MBA, who is retiring but will continue to serve as a consultant. Mr. Prechtl has...
Cleveland Clinic Cancer Center Oncologists Earn National Recognition as Institution Expands Staff
Cleveland Clinic Cancer Center recently announced news about the following physicians, including the appointment of four new staff members: Shilpa Gupta, MD, received a 2-year, $573,850 grant from the Department of Defense to study biomarkers of response and resistance to immunotherapy and to apply ...
NCI Funds Studies of Impact of Telehealth and Telemedicine Capacity for Rural Patients Amid COVID-19 Pandemic
The National Cancer Institute (NCI) has awarded the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) a supplemental grant (P30) to study the role of telehealth in delivering cancer care during the COVID-19 pandemic. The project will evaluate the impact of telehealth on health outcomes, patient...
NRG Oncology Biospecimen Bank Awarded NCI Funding for Next 6 Years
The NRG Oncology Biospecimen Bank will be awarded an additional 6 years of funding from the National Cancer Institute (NCI). This grant will provide biospecimen banking support for the NCI National Clinical Trials Network (NCTN) group NRG Oncology. During the peer-review grant-renewal process, the...
Fox Chase Cancer Center Welcomes New Staff Members
Fox Chase Cancer Center has announced the hiring of three new staff members who will begin their work with the cancer center this month. Brandon Bachert, MD, joins the Department of Diagnostic Imaging as Assistant Professor. He comes to Fox Chase from Albert Einstein Healthcare Network, where he...
American Cancer Society and Flatiron Health Announce Recipients of the Real-World Data Impact Award
Three American Cancer Society (ACS) researchers will receive the Real-World Data Impact Award. The joint grant-making program, supported by the ACS and Flatiron Health, seeks to accelerate cancer research and improve treatment and outcomes for patients. The researchers, already funded by the ACS,...
CICERO Software May Enable Detection of Cancer-Causing Gene Fusions
After years of development, engineering, and enhancement, researchers at St. Jude Children’s Research Hospital in Memphis have made available a software system that enables better detection of gene fusions. The system, called CICERO, offers additional insights into cancers as well as new targets...
Translated Tool From NCCN Measures Mental Health ‘Temperature’ of People With Cancer
The National Comprehensive Cancer Network® (NCCN) recently announced that the NCCN Distress Thermometer has been translated into 46 languages. This free resource helps providers worldwide identify and address the multifactorial aspects of distress patients with cancer can experience. The NCCN...
Dr. Jimmie C. Holland’s Research Has Long Underscored the Importance of Caring for the Whole Patient
Jimmie C. Holland, MD, who served as the inaugural Chairman of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center, died on December 24, 2017, at the age of 89. The ASCO Post paid tribute to Dr. Holland in its January 25, 2018, issue. Here, as part of our ...
Lost in Translation: A Fisherman’s Tale
The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
National Comprehensive Cancer Network Celebrates Its 25th Year
It was February 1996, and the first annual meeting of the National Comprehensive Cancer Network® (NCCN®) was drawing to a close, when Chief Executive Officer (CEO) Bruce R. Ross, MD, invited comments from the floor. An oncologist who had attended at the urging of a friend—somewhat reluctantly—stood ...
Mustafa Raoof, MD, MS, Recognized for Pancreatic Cancer Research
Mustafa Raoof, MD, MS, a surgical oncologist and researcher specializing in gastrointestinal cancers at City of Hope, was recently awarded a Pancreatic Cancer Action Network Career Development Award (PanCAN) and a Young Investigator Award from the National Comprehensive Cancer Network® (NCCN). “I’m ...
SABCS Teams With Tigerlily Foundation for #InclusionPledge to Improve Health-Care Equity for Black Women
In the midst of a global pandemic, while the entire country grapples with recent events highlighting systemic racism, national breast cancer patient organizations are committing to an unprecedented health-equity initiative that focuses on diversity and inclusion. As a result, the San Antonio Breast ...
Roswell Park Gynecologic Oncologists Awarded Leadership Roles
Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, announced the promotion of three staff members to leadership positions. “The dedication of this trio of physicians to their patients and Roswell Park’s mission is unmatched,” said Dr. Odunsi, who also...
Expert Point of View: David Sallman, MD
David Sallman, MD, an assistant member of the Malignant Hematology Department of Moffitt Cancer Center and Research Institute, Tampa, Florida, commented on the IMerge and QUAZAR studies for The ASCO Post. As background, he noted the “predominant struggle” of patients with lower-risk myelodysplastic ...
Edward Chu, MD, MMS, to Lead Cancer Medicine at Albert Einstein College of Medicine and Montefiore Health System
Albert Einstein College of Medicine and Montefiore Health System recently announced that Edward Chu, MD, MMS, has been named Director of the National Cancer Institute-designated Albert Einstein Cancer Center, Vice President for Cancer Medicine at Montefiore Medicine, Professor of Medicine and of...
Huntsman Cancer Institute Brings Home Cancer Care to Rural Utah
A $4.5 million gift from the Huntsman family will fund the expansion of a unique program at Huntsman Cancer Institute (HCI) at the University of Utah that brings specialty cancer care directly to patients in their homes. With this gift, HCI’s Huntsman at Home will extend to rural Utah. The goal is...
Expert Point of View: Stephen M. Ansell, MD, PhD
Stephen M. Ansell, MD, PhD, Professor of Medicine in the Department of Hematology at the Mayo Clinic, Minnesota, underscored the importance of the HD17 trial results. “These data show, in a randomized fashion, that a PET-directed approach when using more intensive chemotherapy allows for the...
Geraldine Jacobson, MD, MPH, MBA, FASTRO, Elected as Future Chair of ASTRO
The members of the American Society for Radiation Oncology (ASTRO) have elected four new officers to ASTRO’s Board of Directors. Geraldine Jacobson, MD, MPH, MBA, FASTRO, will begin her term as President-Elect in October during ASTRO’s 62nd Annual Meeting, alongside Gopal K. Bajaj, MD, MBA,...
Incorporating Immunotherapy Into Treatment of Early-Stage NSCLC
There is a strong rationale for incorporating immunotherapy into the treatment of early-stage non–small cell lung cancer (NSCLC), given the breakthrough results with PD-1 checkpoint inhibitors as monotherapy, combined with immunotherapy, or combined with chemotherapy in advanced-stage NSCLC. As...
Juanita L. Merchant, MD, PhD, Appointed to Ludwig Institute’s Scientific Advisory Committee
Ludwig Cancer Research recently welcomed Juanita L. Merchant, MD, PhD, to the Scientific Advisory Committee of the Ludwig Institute for Cancer Research. Dr. Merchant is a practicing clinician and an accomplished researcher at the University of Arizona, Tucson, where she is Professor and Chief of...
Measuring the Impact of the Plunge in Cancer Screenings During the COVID-19 Pandemic
As outbreaks of the COVID-19 pandemic spiked across the country earlier this year, federal health officials and cancer societies advised people to delay seeking routine cancer screenings, including mammograms and colonoscopies, to keep them out of medical centers and away from potential exposure to ...
Memorial Sloan Kettering Launches Women in Science Endeavor
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of the Marie-Josée Kravis Women in Science Endeavor (WiSE) to provide financial and professional support to women scientists pursuing biomedical research at MSK, pledging its commitment to gender equity in science and ...
Fred Hutch Announces New Additions and Leadership to Board of Trustees
Fred Hutchinson Cancer Research Center announced the addition of two new members to its Board of Trustees, along with a new Chair and Vice Chair. Kathy Surace-Smith, JD, will take over the Board Chair position from Matt McIlwain, MBA, who now becomes immediate Past Chair. Ms. Surace-Smith, who is...
SNMMI Names Alan B. Packard, PhD, as President, and Richard L. Wahl, MD, as President-Elect
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2020 Virtual Annual Meeting on July 11–14, during which officers for the current term were elected, including Alan B. Packard, PhD, as President, and Richard L. Wahl, MD, as President-Elect. Raising Recognition “SNMMI’s strength ...
Pediatric Hematologist/Oncologist Yoram Unguru, MD, MS, MA, Explains the Economic Origins of Drug Shortages and Other Ethical Issues
Improvements in protocol-driven clinical trials and supportive care for children and adolescents with cancer have markedly reduced mortality rates over the past 5 decades. Yet, along with clinical advances, oncologists and their young patients with cancer face a host of ethical issues, made more...
Jessica Y. Islam, PhD, MPH, on COVID-19 Preventive Behaviors Among Cancer Survivors
Jessica Y. Islam, PhD, MPH, of the UNC Lineberger Comprehensive Cancer Center, discusses findings from the COVID-19 Impact Survey, which showed that cancer survivors are adhering to many of the recommended COVID-19 preventive behaviors, such as wearing masks and social distancing.
Nancy E. Davidson, MD, on Bringing Patients With Cancer Back to the Clinic During the COVID-19 Pandemic
Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, talks about a panel she moderated in which speakers discussed the importance of communicating with patients to ease their concerns about cancer care during the COVID-19 pandemic, allocating protective gear for the most vulnerable...
Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease
A new study published by Minami et al in the Journal of the American College of Surgeons found that longer time from diagnosis to surgical treatment did not lower overall survival in women with early-stage breast cancer. These findings may be reassuring for women with early-stage breast cancer who...
Refinement of European LeukemiaNet Classification Recommendations for Younger Adults With AML
Findings from a study published by Eisfeld et al in the journal Leukemia could refine an important set of prognostic and treatment recommendations for younger adult patients with acute myeloid leukemia (AML). The retrospective study evaluated the molecular characteristics and outcomes of 863...
FDA Pipeline: Designations in Kidney and Lung Cancers, Myelodysplastic Syndromes, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has issued designations and accepted applications for novel agents, as well as approved companion diagnostics. We summarize these regulatory movements below. Breakthrough Therapy Designation for MK-6482 in von Hippel-Lindau...
